Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, has appointed Dr Helen Horton as Chief Research Officer. Horton will be responsible for developing a pipeline of products that leverage Touchlight's "doggybone" DNA (dbDNA) platform, both in-house and with partners, for the company's therapeutic arm, Touchlight Genetics.
Horton joins from Johnson & Johnson, where, as a Senior Scientific Director, she directed immune strategies aimed at curing chronic viral infections and advanced several programmes into the clinic. She has over twenty years of experience in immunogenetics, immune modulation, and infectious diseases.
Prior to Johnson and Johnson, Horton worked as Associate Professor at the Center for Infectious Disease Research in Seattle (WA), and as Affiliate Associate Professor at the University of Seattle. She has a PhD in Biology from the University of York, and a BSc (Hons) in Biochemistry and Pharmacology from the University of Leeds.
Jonny Ohlson, founder and CEO of Touchlight, said: "Helen has vast experience in DNA vaccines. Her in-depth knowledge and expertise in this field will immediately accelerate our mission to develop the next generation of genetic medicines."
Dr. Horton commented on her appointment: "Touchlight has a revolutionary platform with its dbDNA technology and a very talented team. Currently, governments are looking to genetic vaccines to help us tackle diseases such as COVID-19. I believe Touchlight's technology will be front and centre of this fight which is why I am excited to be joining at this time."
